Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.11 USD | +2.03% | +20.67% | +13.57% |
Apr. 16 | BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating | MT |
Apr. 09 | Xencor Names Bart Cornelissen as Chief Financial Officer | MT |
Business Summary
Number of employees: 280
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Monoclonal Bispecific Antibody and Cytokine Therapeutics
100.0
%
| 165 | 100.0 % | 168 | 100.0 % | +2.28% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Global
100.0
%
| 165 | 100.0 % | 168 | 100.0 % | +2.28% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bassil Dahiyat
FOU | Founder | 53 | 97-07-31 |
John Desjarlais
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-06-30 |
Charles Liles
IRC | Investor Relations Contact | - | - |
Jennifer Sandoz
HRO | Human Resources Officer | - | - |
Celia Eckert
LAW | General Counsel | 52 | 19-09-09 |
Jeremy Grunstein
PRN | Corporate Officer/Principal | - | 19-05-22 |
David Szymkowski
PRN | Corporate Officer/Principal | 60 | 01-12-31 |
Raphael Clynes
PRN | Corporate Officer/Principal | - | 17-06-07 |
Nancy Valente
PRN | Corporate Officer/Principal | 66 | 22-09-07 |
Dane Leone
PRN | Corporate Officer/Principal | - | Jan. 01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kevin Gorman
BRD | Director/Board Member | 66 | 17-04-13 |
Director/Board Member | 71 | 17-12-18 | |
Director/Board Member | 70 | 15-03-17 | |
Bassil Dahiyat
FOU | Founder | 53 | 97-07-31 |
Kurt Gustafson
BRD | Director/Board Member | 56 | 14-07-24 |
69 | - | ||
Barbara Klencke
BRD | Director/Board Member | 66 | 23-09-14 |
Director/Board Member | 60 | 19-12-17 | |
Nancy Valente
PRN | Corporate Officer/Principal | 66 | 22-09-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 61,647,493 | 61,064,703 ( 99.05 %) | 0 | 99.05 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
INMUNE BIO, INC. 10.46% | 1,885,533 | 10.46% | 22,155,013 $ |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.57% | 1.49B | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- XNCR Stock
- Company Xencor, Inc.